In a notable year-end market move, Molina Healthcare (MOH) emerged as a standout performer within the S&P 500 on the penultimate trading day of 2025. Its stock surged as much as 5% intraday, a rally attributed not to sector-wide news but to public endorsement from famed investor Michael Burry.
Burry, renowned for his prescient bet against the housing market before the 2008 financial crisis and popularized by the book and film “The Big Short,” recently highlighted the managed care company’s fundamentals. He suggested Molina could become an acquisition target if its valuation remains depressed. This is not his first bullish signal on the stock; Burry disclosed a long position via social media in November and has since doubled down, even comparing the potential opportunity to Warren Buffett’s investment in GEICO and calling it a possible “generational buy.”
Molina Healthcare is a leading provider of managed healthcare services, primarily focused on government-sponsored programs like Medicaid and Medicare. As of late 2021, it served approximately 5.2 million members across 18 U.S. states.
Burry’s optimism finds company in institutional action. Cobalt Capital Management disclosed a new, significant position in Molina Healthcare on November 13, 2025. The fund acquired 115,000 shares valued at approximately $22 million, making it the fund’s fourth-largest holding and accounting for over 10% of its reported 13F assets. This substantial commitment comes as Molina’s stock trades near multi-year lows, having declined roughly 40% year-to-date.
The sizable institutional stake suggests some investors believe the market narrative has diverged from Molina’s operational reality. The company’s revenue model is based on fixed-rate, per-member government contracts, making its financial performance critically dependent on managing medical costs effectively. This structure offers operational leverage when cost trends are stable but creates pressure when medical costs outpace expectations.
Recent challenges, including missteps in rate negotiations and elevated medical costs, have driven the stock price down sharply. However, the recent institutional investment implies a view that the company’s core business advantages and long-term compounding potential remain intact despite these cyclical headwinds.
For investors, the key question is whether Molina can successfully reset pricing and restore margin clarity in upcoming contract cycles. If management can align medical cost trends with reimbursement rates and maintain bidding discipline, the current depressed valuation may present an opportunity rather than a permanent impairment.
Amid endorsement from a high-profile contrarian investor and concrete institutional buying, this deeply sold-off healthcare stock is regaining investor attention. Its ability to leverage the stability of government-sponsored business and execute on cost containment will be pivotal in determining its next chapter.
